NMAX vs NRDS

NMAX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite maintaining a low debt-to-equity ratio and acceptable liquidity, the company is suffering from severe profitability collapse with an ROE of -205.18% and a profit margin of -52.57%. The stock has experienced a catastrophic long-term decline, losing 92.5% of its value over five years. While analyst target prices suggest a significant upside, the deterministic data points to a high-risk profile with no current evidence of a sustainable turnaround.

NRDS exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.04). However, the stock is currently trading at a premium to both its Graham Number ($8.7) and Intrinsic Value ($4.48). While revenue growth remains robust at 22.6%, a severe collapse in earnings growth (-62.5%) and consistent earnings misses create a significant fundamental disconnect. The combination of bearish insider activity and a poor earnings track record offsets the strong liquidity and low valuation multiples.